Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.
CD4
antimetabolite
methotrexate
mycophenolate mofetil
uveitis
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
02 Jan 2022
02 Jan 2022
Historique:
pubmed:
12
8
2020
medline:
17
3
2022
entrez:
12
8
2020
Statut:
ppublish
Résumé
Sub-analysis of the FAST Trial comparing change in CD4 (∆CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX). Patients were randomly allocated to 1.5 g twice daily MMF or 25 mg weekly MTX. Individuals with CD4 counts at baseline, 6 months (or treatment failure prior), and 12 months (or treatment failure between 6 and 12 months) were included. The association between treatment and ∆CD4 (cells/μL) was analyzed using multivariable linear regression. There was no significant difference in ∆CD4 between MMF and MTX at 6 months (-31.7 cells/μL for MMF compared to MTX; 95% CI: -358.2 to 294.8, There was no significant difference in ∆CD4 between MMF and MTX from baseline to 12 months, suggesting that MMF does not confer additional risk of CD4 lymphopenia in uveitic patients.ClinicalTrials.gov Identifier: NCT01829295.
Identifiants
pubmed: 32779952
doi: 10.1080/09273948.2020.1774906
pmc: PMC7876156
mid: NIHMS1599753
doi:
Substances chimiques
Antimetabolites
0
Immunosuppressive Agents
0
Steroids
0
Mycophenolic Acid
HU9DX48N0T
Methotrexate
YL5FZ2Y5U1
Banques de données
ClinicalTrials.gov
['NCT01829295']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-202Subventions
Organisme : NEI NIH HHS
ID : U10 EY021125
Pays : United States
Références
J Rheumatol. 2008 Apr;35(4):572-9
pubmed: 18381794
Cleve Clin J Med. 1990 May;57(3):232-41
pubmed: 1972665
J Rheumatol. 2008 Apr;35(4):550-2
pubmed: 18398948
Transplantation. 2011 Feb 15;91(3):309-16
pubmed: 21107304
Br J Ophthalmol. 2016 Oct;100(10):1393-6
pubmed: 26729767
J AIDS Clin Res. 2010 Oct 8;1(1):1-4
pubmed: 21479149
Am J Med Sci. 2016 Sep;352(3):239-44
pubmed: 27650226
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3475-82
pubmed: 18421089
RMD Open. 2016 Jun 09;2(1):e000287
pubmed: 27335660
JAMA. 2019 Sep 10;322(10):936-945
pubmed: 31503307
Clin Rheumatol. 2014 Feb;33(2):175-85
pubmed: 23934385
Cochrane Database Syst Rev. 2015 Dec 03;(12):CD007746
pubmed: 26633102
Clin Exp Immunol. 2012 Apr;168(1):68-74
pubmed: 22385240
Cells. 2019 Aug 10;8(8):
pubmed: 31405169
Bull NYU Hosp Jt Dis. 2007;65(3):168-73
pubmed: 17922664
Lupus. 2005;14 Suppl 1:s2-8
pubmed: 15803924
J Heart Lung Transplant. 2002 Oct;21(10):1074-9
pubmed: 12398872
Int J Infect Dis. 2017 Apr;57:108-115
pubmed: 28223177
Transplant Proc. 2003 Jun;35(4):1355-9
pubmed: 12826158
Medicine (Baltimore). 2019 Sep;98(39):e16997
pubmed: 31574798
Respir Med. 2014 Nov;108(11):1663-9
pubmed: 25301291
Transplantation. 2019 Jun;103(6):1131-1139
pubmed: 30801552
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
J Rheumatol. 2001 Aug;28(8):1793-9
pubmed: 11508581
Transplant Proc. 2002 Sep;34(6):2377-8
pubmed: 12270445
Inflamm Res. 2012 Nov;61(11):1229-39
pubmed: 22802109
Antivir Ther. 2017;22(8):659-668
pubmed: 28291735
PLoS One. 2010 Feb 05;5(2):e9088
pubmed: 20140091
Clin Exp Immunol. 2007 May;148(2):288-95
pubmed: 17286800
Expert Rev Clin Immunol. 2015;11(12):1353-64
pubmed: 26364748